Safety of Raloxifene in Hemodialysis Patients


avatar Didy Jacobsen 1 , *

Geriatric Department, Radboud University Medical Center, Nijmegen, The Netherlands

how to cite: Jacobsen D. Safety of Raloxifene in Hemodialysis Patients. Int J Endocrinol Metab. 2012;10(4): 638-639.


  • 1.

    Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando Y, et al. Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients With Type 2 Diabetes. Int J Endocrinol Metab. 2012;10(2):464-9.

  • 2.

    Amerling R, Harbord NB, Pullman J, Feinfeld DA. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif. 2010;29(3):293-9. [PubMed ID: 20090316].

  • 3.

    Tanaka M, Itoh K, Matsushita K, Moriishi M, Kawanishi H, Fukagawa M. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis. Ther Apher Dial. 2011;15:62-6. Suppl 1. [PubMed ID: 21595855].

  • 4.

    Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, et al. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD–mineral and bone disorder (CKD-MBD). Am J Kid Dis. 2010;55(5):773-99. [PubMed ID: 20363541].

  • 5.

    Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996;49(5):1428-34. [PubMed ID: 8731110].

  • 6.

    Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000;35(4 Suppl 1):S117-31.

  • 7.

    Churchill DN, Taylor DW, Cook RJ, LaPlante P, Barre P, Cartier P, et al. Canadian Hemodialysis Morbidity Study. Am J Kidney Dis. 1992;19(3):214-34. [PubMed ID: 1553966].

  • 8.

    Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290(13):697-701. [PubMed ID: 4813742].

  • 9.

    Rostand SG, Kirk KA, Rutsky EA. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int. 1982;22(3):304-8. [PubMed ID: 7176333].

  • 10.

    Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D. Raloxifene and risk for stroke based on the framingham stroke risk score. Am J Med. 2009;122(8):754-61. [PubMed ID: 19540454].

  • 11.

    Kagan A, Dawber TR, Kannel WB, Revotskie N. The Framingham study: a prospective study of coronary heart disease. Fed Proc. 1962;21(4):52-7. Pt 2. [PubMed ID: 14453051].

  • 12.

    Kannel WB. Coronary heart disease risk factors in the elderly. Am J Geriatr Cardiol. 2002;11(2):101-7. [PubMed ID: 11872968].

  • 13.

    Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33-50. [PubMed ID: 13751193].

  • 14.

    Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83(1):356-62. [PubMed ID: 1984895].

  • 15.

    Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002;13(7):1918-27. [PubMed ID: 12089389].